CN106008362A - Preparation method of novel pyrimidine derivative - Google Patents
Preparation method of novel pyrimidine derivative Download PDFInfo
- Publication number
- CN106008362A CN106008362A CN201610349669.0A CN201610349669A CN106008362A CN 106008362 A CN106008362 A CN 106008362A CN 201610349669 A CN201610349669 A CN 201610349669A CN 106008362 A CN106008362 A CN 106008362A
- Authority
- CN
- China
- Prior art keywords
- methyl
- fluoro
- ethyl
- pyrimidine
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims description 58
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 22
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 20
- OFPWIXYGAJDWPC-UHFFFAOYSA-N 2-ethyl-1h-pyrimidin-6-one Chemical compound CCC1=NC=CC(=O)N1 OFPWIXYGAJDWPC-UHFFFAOYSA-N 0.000 claims description 14
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 claims description 10
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 10
- RILVNLMOTMFTMQ-UHFFFAOYSA-N 2-ethylpyrimidine Chemical compound CCC1=NC=CC=N1 RILVNLMOTMFTMQ-UHFFFAOYSA-N 0.000 claims description 9
- ITILUTBFZOWWQM-UHFFFAOYSA-N 4-fluoro-4-methyl-3-oxopentanoic acid Chemical compound FC(C(CC(=O)O)=O)(C)C ITILUTBFZOWWQM-UHFFFAOYSA-N 0.000 claims description 8
- 239000012279 sodium borohydride Substances 0.000 claims description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- -1 potassium tert-butoxide Ester Chemical class 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 claims description 4
- 238000005893 bromination reaction Methods 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 4
- RUIAUVYVCXIZFV-UHFFFAOYSA-N 1-methyl-2h-isoindole Chemical compound C1=CC=CC2=C(C)NC=C21 RUIAUVYVCXIZFV-UHFFFAOYSA-N 0.000 claims description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052756 noble gas Inorganic materials 0.000 claims 1
- 150000007984 tetrahydrofuranes Chemical group 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 11
- 239000002547 new drug Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 4
- 208000017667 Chronic Disease Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 201000004384 Alopecia Diseases 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract 2
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 23
- 238000012805 post-processing Methods 0.000 description 19
- 208000035126 Facies Diseases 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000013019 agitation Methods 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- BHIWKHZACMWKOJ-UHFFFAOYSA-N methyl isobutyrate Chemical compound COC(=O)C(C)C BHIWKHZACMWKOJ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 150000000644 6-membered heterocyclic compounds Chemical class 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- WDAXFOBOLVPGLV-UHFFFAOYSA-N isobutyric acid ethyl ester Natural products CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical group C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 238000009333 weeding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention provides a preparation method of a novel pyrimidine derivative. The pyrimidine derivative is [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride. The pyrimidine derivative is a new medical intermediate for new drug research and development and screening. The pyrimidine derivative can be applied to the new drug research and development and screening for treating various chronic diseases such as diabetes and alopecia; a synthesis method of the compound also has the advantages of easiness in operation, high efficiency and low raw material cost; and the synthesis path has the advantages of simple and convenient technology and adaptability to factory enlarged production.
Description
Technical field
The present invention relates to the preparation method of a kind of new pyrimidine heterocyclic compounds, be specifically related to a kind of new pyrimidine compound and preparation method thereof.
Background technology
Pyrimidine is a very important heterocyclic compound of class, is widely used in medicine and pesticide field, and numerous studies show that this compounds has preferable biological activity, has important application at parasite killing, sterilization, weeding, antiviral, the aspect such as anticancer.Due to pyrimidine compound have efficiently, the advantage such as low toxicity, model of action are unique；Therefore its MOLECULE DESIGN, synthesis remain a field the most active in heterocyclic compound research with bioactivity research.
Pyrimidines refers to the 6-membered heterocyclic compound in molecular structure containing two nitrogen-atoms, with pyridazine, pyrazine isomers each other.There is special ultraviolet spectra owing to molecular structure existing conjugated double bond.Soluble in water, its alkalescence is more weak than pyridine, is difficult to electrophilic substitution reaction, only in 5-position, bromination reaction can occur, it is impossible to nitrification and sulfonating reaction occur, but is easier to nucleophilic displacement of fluorine, the derivant of pyrimidine is widely present in nature, such as sulfadiazine, barbital, vitamin B1 etc..In nucleic acid, having 3 kinds of important miazines bases, they are uracil, thymus pyrimidine, cytosine, main containing cytosine and thymus pyrimidine in DNA, main containing cytosine and uracil, possibly together with a small amount of miazines modified base in some nucleic acid in RNA.Many medicines, such as sulfadiazine, trimethoprim, Ismipur all contain pyrimidine ring.
Summary of the invention
The shortcoming of prior art in view of the above, it is an object of the invention to provide the preparation method of a kind of novel poyrimidine derivatives.
For achieving the above object and other relevant purposes, the present invention is by including that the technical scheme recorded as follows realizes:
A kind of preparation method of structural formula compound as shown in formula L, described compound is [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride, and formula L is:
Described method comprises the steps:
1) 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde is added to the water, is dividedly in some parts sodium borohydride reaction and obtains 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol；
2) 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol, triphenylphosphine and phthalimide react acquisition 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine under solvent and inert gas conditions with diethyl azodiformate } methyl-isoindole quinoline-1,3-diketone；
3) 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } methyl-isoindole quinoline-1,3-diketone and hydrazine hydrate in a solvent and under counterflow condition reaction obtain [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride.
Preferably, above-mentioned steps 1) described in sodium borohydride be dividedly in some parts.
Preferably, above-mentioned steps 1) described in the molar ratio of 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde and sodium borohydride be 1:(0.3～0.5).Preferably, above-mentioned steps 1) at 0～10 DEG C add sodium borohydride.Preferably, above-mentioned steps 1) at 0～5 DEG C add sodium borohydride.
It is highly preferred that step 1) reaction carries out post processing to product after terminating, and post processing includes extracting organic facies, precipitation.It is highly preferred that the solvent used during extraction is dichloromethane.It is highly preferred that above-mentioned precipitation is to use anhydrous sodium sulfate to be dried, and concentrated.
Preferably, above-mentioned steps 2) in reaction temperature be-10～25 DEG C.Preferably, above-mentioned steps 2) in 5 DEG C and following temperature and drip diethyl azodiformate under nitrogen protection.It is highly preferred that after dropping diethyl azodiformate, reaction is carried out at ambient temperature.
Preferably, above-mentioned steps 2) in 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol, triphenylphosphine, the mol ratio of phthalimide and diethyl azodiformate be 1:1.1:1.1:1.1.
Preferably, above-mentioned steps 2) in, reaction also includes the post processing to product after terminating, and post processing includes extracting organic facies, precipitation.It is highly preferred that post-processing step includes concentrating THF, then extract.It is highly preferred that use methyl tertiary butyl ether(MTBE) in Cui Qu.The organic facies that extraction obtains sodium hydroxide solution washs, and the aqueous phase of extraction is extracted with ethyl acetate acquisition organic facies.By the step of organic facies precipitation for be dried with anhydrous sodium sulfate.It is highly preferred that after being dried, concentrate dry, mix silica gel and cross post, PE:EA=4:1 rushes post, obtains product MTBE making beating, dries to obtain 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } methyl-isoindole quinoline-1,3-diketone.
Preferably, step 3) in, 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } methyl-isoindole quinoline-1,3-diketone is 1:(2～3 with the mol ratio of hydrazine hydrate).Preferably, step 3) in possibly together with solvent.It is highly preferred that described solvent is ethanol.
Preferably, above-mentioned steps 3) in, reaction also includes post processing after terminating, post processing include rotation steam, with MTBE re-dissolved, filter, use HCl wash to aqueous phase, aqueous phase washs with DCM again, then use sodium hydroxide solution to regulate aqueous phase to pH=11, then use DCM extraction, extract anhydrous sodium sulfate to be dried；The dried HCl that is passed through below 10 DEG C, to becoming salt, filters, and drying is to [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride.
The invention also discloses the preparation method of described 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde, comprise the steps:
1) the bromo-6-of the chloro-5-of 4-(2-(2-fluoro-2-methyl) ethyl-pyrimidin and unifor back flow reaction in chloroform obtains N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide；
2) N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide back flow reaction acquisition bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine in alkaline aqueous solution；
3) the bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine first reacts with isopropylmagnesium chloride, then reacts acquisition 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde with N-formyl-morpholine.
Preferably, step 1) in, (2-(2-fluoro-2-methyl) ethyl-pyrimidin is 1:2 with the molar ratio of unifor to the bromo-6-of the chloro-5-of 4-.Preferably, step 1) in reaction under reflux conditions carry out.Preferably, above-mentioned steps 1) in, reaction carries out post processing to product after terminating, and post processing includes lowering the temperature, filter, wash and drying.
Preferably, step 2) in, N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide is dividedly in some parts in reaction system.Preferably, step 2) in, reaction carries out post processing to product after terminating.Preferably, described post processing includes extraction, is dried, and concentrates and does to obtain crude product, and crude product decompression distillation collects fraction 20Pa 50～60 DEG C.It is highly preferred that use MTBE in Cui Qu.
Preferably, above-mentioned steps 3) in reaction system in possibly together with solvent.It is highly preferred that described solvent is THF.Preferably, above-mentioned steps 3) in, the mol ratio that the bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine, isopropylmagnesium chloride feed intake with N-formyl-morpholine is 1:1.1:2.Nitrogen displacement and temperature for-50 DEG C and following in the case of add isopropylmagnesium chloride.And temperature for-50 DEG C and following in the case of add N-formyl-morpholine.
Above-mentioned steps 3) in reaction terminate after use saturated ammonium chloride cancellation, product is carried out post processing, post processing includes extracting organic facies, washs, is dried, concentrates dry acquisition crude product, and mistake post obtains 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde.Preferably, MTBE is selected in extraction.Preferably, post is crossed for using PE:MTBE=15:1 to rinse.
(preparation method of 2-(2-fluoro-2-methyl) ethyl-pyrimidin, in order to use the bromo-6-of 5-, (2-(2-fluoro-2-methyl) ethyl-4-pyrimidone obtains with phosphorus oxychloride reaction to the invention also discloses the 4-bromo-6-of chloro-5-.
Preferably, the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone and the mass ratio 1:(3～5 that feeds intake of phosphorus oxychloride).Preferably, (2-(2-fluoro-2-methyl) ethyl-4-pyrimidone is dividedly in some parts in reaction system the bromo-6-of 5-.Preferably, above-mentioned reaction is under reflux conditions carried out.Preferably, reaction concentrates dry phosphorus oxychloride after terminating, use frozen water cancellation, extract with MTBE, be dried, and crosses post, pull an oar with PE after concentration, the bromo-6-of the chloro-5-of drying 4-(2-(2-fluoro-2-methyl) ethyl-pyrimidin.Preferably, it is dried employing anhydrous sodium sulfate to be dried.Preferably, use PE directly to rush post when crossing post and obtain product.
The invention also discloses the bromo-6-of 5-(preparation method of 2-(2-fluoro-2-methyl) ethyl-4-pyrimidone, for using the method that comprises the steps to obtain:
1) 2-fluorine isobutyrate reacts generation 4-fluoro-4-methyl-3-oxo-pentanoate in a solvent with methyl acetate and potassium tert-butoxide；
2) 4-fluoro-4-methyl-3-oxo-pentanoate and formamidine acetate react generation [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone in a solvent and in the basic conditions；
3) [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone generates the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone with bromine generation bromination reaction in a solvent.
Preferably, said method step 1) in, solvent is tetrahydrofuran THF.Preferably, solvent also has methyl acetate.Preferably, step 1) in, 2-fluorine isobutyrate, methyl acetate are 1:1.2:1.3 with the mol ratio of potassium tert-butoxide.Preferably, step 1) in reaction temperature be 50～70 DEG C.For example, 65 DEG C.Preferably, step 1) in carry out post processing after completion of the reaction, the technique of post processing includes concentrating dry THF, adding mixture of ice and water, and regulation pH is 3, extracts, washs, is dried, concentrate to do and i.e. obtain 4-fluoro-4-methyl-3-oxo-pentanoate.Preferably, extraction uses MTBE.
Preferably, said method step 2) in solvent be methanol, it be alkaline for using Feldalat NM regulation pH.Preferably, above-mentioned steps 2) in, 4-fluoro-4-methyl-3-oxo-pentanoate is 1:(1.2～1.5 with the mol ratio of formamidine acetate).Preferably, step 2) in reaction temperature be 50～70 DEG C.For example, 65 DEG C.Preferably, said method step 2) in carry out post processing after completion of the reaction, the technique of post processing includes filtering and obtains filtrate, concentrates, dries to obtain crude product, and after then pulling an oar with MTBE, filtering drying obtains [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone.
Preferably, said method step 3) in solvent be acetic acid, regulating reactant liquor pH with sodium acetate is faintly acid.Preferably, step 3) in, [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone is 1:1 with the mol ratio of bromine.Preferably, during adding bromine, the temperature controlling reaction system is less than 40 DEG C, and interpolation bromine reacts after terminating and at room temperature carries out.Preferably, reaction uses spherical condensation tube.Preferably, said method step 3) in carry out post processing after completion of the reaction, the technique of post processing includes that acetic acid is fallen in concentration, with acetic acid ethyl dissolution, add water and separate organic facies, aqueous phase is extracted with ethyl acetate, the organic facies washing of extraction acquisition and the dry crude product that obtains, and then concentrates after doing with the MTBE making beating also bromo-6-of drying 5-(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone.
The invention also discloses a kind of midbody compound, described midbody compound is 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol, and the formula J of described compound is:
The invention also discloses the purposes of a kind of midbody compound as described above, for the pharmaceutical intermediate as synthesis [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride.
In the present invention, compound described above has the beneficial effect that the present invention provides the new synthetic method of a kind of medicine intermediate and a kind of midbody compound, used by new drug development screening.With the new drug of structural compounds of the present invention and similar structures compound albumen excited and mould have different inhibitory action, and excite mould inhibition to have the strongest selectivity in different albumen.In treatment chronic disease (WO2015095679) such as: in rheumatoid arthritis, psoriatic new drug development, similar structures compound is modified as new drug fragment and has been used widely.As follows:
New compound may be used in the new drug development screening of the treatment treatment various chronic disease such as diabetes, baldness, the synthetic method of this compound also has simple to operate, efficient, the advantage that cost of material is low, this synthetic route has the advantage that technique is simple and convenient, be suitable for factory's amplification production.
Accompanying drawing explanation
Fig. 1 is the synthetic route chart of structure compound as shown in formula E.
Fig. 2 is the synthetic route chart of structure compound as shown in formula F.
Fig. 3 is the synthetic route chart of structure compound as shown in formula G.
Fig. 4 is the synthetic route chart of structure compound as shown in formula H.
Fig. 5 is the synthetic route chart of structure compound shown in formula I.
Fig. 6 is the synthetic route chart of structure compound as shown in formula J.
Fig. 7 is the synthetic route chart of structure compound as shown in formula K.
Fig. 8 is the synthetic route chart of structure compound as shown in formula L.
In Fig. 1～8:
A is 2-fluorine isobutyrate and ethyl acetate；
B is potassium tert-butoxide；
C is 4-fluoro-4-methyl-3-oxo-pentanoate；
D is [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone；
E is the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone；
F is the 4-bromo-6-of chloro-5-(2-(2-fluoro-2-methyl) ethyl-pyrimidin；
G is N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide；
H is the bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine；
I is 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde；
J is 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol；
K is 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } methyl-isoindole quinoline-1,3-diketone；
L is [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride.
Detailed description of the invention
Below by way of specific instantiation, embodiments of the present invention being described, those skilled in the art can be understood other advantages and effect of the present invention easily by the content disclosed by this specification.The present invention can also be carried out by the most different detailed description of the invention or apply, and the every details in this specification can also carry out various modification or change based on different viewpoints and application under the spirit without departing from the present invention.
Embodiment 1
The synthesis of 4-fluoro-4-methyl-3-oxo-pentanoate:
THF (25L) is joined in the reactor of 50L, start mechanical agitation, add potassium tert-butoxide (10920g, 97.5mol, 1.3eq), then dropping 2-flaoro methyl isobutyrate (9000g, 75mol, 1eq) and methyl acetate (6660g, 90mol, mixture 1.2eq), drips and is warming up to 65 DEG C after finishing, and reaction is overnight.TLC (PE:EA=4:1) shows after completion of the reaction, concentrates THF, remains about 20L, add 20L mixture of ice and water, adjust pH=3 with 6M HCl, then extract (10L × 2) with MTBE, merging organic facies saturated aqueous common salt washed once, anhydrous sodium sulfate is dried.Concentrate and do to obtain 10000g crude product, yield 74.07%.
Embodiment 2
6-(synthesis of 2-(2-fluoro-2-methyl) ethyl-4-pyrimidone:
Methanol (25L) is joined in 50L reactor, starts mechanical agitation, be dividedly in some parts Feldalat NM (3162g, 58.56mol, 1.9eq), have temperature-rise period.It is cooled to less than 40 DEG C, adds formamidine acetate (3852g, 37.04mol, 1.2eq), then dropping compound 4-fluoro-4-methyl-3-oxo-pentanoate (5000g, 30.86mol, 1eq).Dripping and be warming up to 65 DEG C after finishing, reaction is overnight.TLC (PE:EA=1:1) display raw material reaction is complete.It is passed through HCl gas to system pH=5. to reaction system, stands overnight after having led to.In bottle, solid filters, filter cake acetone heating washing 3 times, filters, merging filtrate and cleaning mixture, concentrates and dry obtain crude product, filter after then pulling an oar with MTBE, dries and there are product 3300g, yield 68.5%.Ms (M+1=157.10)；1H NMR(300MHz,CDCl3) δ 13.3 (br, 1H), 8.15 (s, 1H), 6.69 (s, 1H), 1.69 (s, 3H), 1.61 (s, 3H). (mother solution can be left and taken and cast step bromination).
Embodiment 3
The bromo-6-of the 5-(synthesis of 2-(2-fluoro-2-methyl) ethyl-4-pyrimidone
20L reaction bulb, prepares 0-100 DEG C of thermometer, mechanical agitation, spherical condensation tube.By compound 6-, (2-(2-fluoro-2-methyl) ethyl-4-pyrimidone (1495g, 9.57mol, 1eq) and sodium acetate (785.3g, 9.57mol, 1.1eq), acetic acid (10L) joins in reaction bulb together.Room temperature dropping bromine (1685,10.53,1eq), dropping process has warming phenomenon, controls temperature and is less than less than 40 DEG C, 1h is stirred at room temperature after adding.TLC (PE:EA=1:1) display raw material reaction is complete.Concentrating 7L acetic acid, add EA (5L), dissolve, the 5L that adds water separates organic facies, and aqueous phase EA extracts (5L × 3), and the organic facies saturated aqueous common salt of merging washed once, and anhydrous sodium sulfate is dried.Concentrate dry rear MTBE making beating, dry to obtain 1538g, yield: 68.02%.Ms (M+1=235,237)；1H NMR(300MHz,CDCl3)δ13.3(br,1H),8.22(s,1H),1.83(s,3H),1.76(s,3H).
Embodiment 4
The bromo-6-of the chloro-5-of 4-(synthesis of 2-(2-fluoro-2-methyl) ethyl-pyrimidin, specifically:
Phosphorus oxychloride (2L) is joined in 3L reaction bulb, start mechanical agitation, be dividedly in some parts the bromo-6-of compound 5-(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone (627g, 2.67mol), it is warming up to backflow after adding, reacts 3h.TLC (PE:EA=2:1) display raw material reaction is complete, concentrates dry phosphorus oxychloride, and the phosphorus oxychloride of frozen water cancellation excess, then with MTBE (1.5L × 2), the organic facies saturated aqueous common salt of merging washed once, and anhydrous sodium sulfate is dried.Concentrating and cross post after doing, PE directly rushes post and obtains product, then pulls an oar with PE, dries to obtain white solid 498g.Yield: 73.67%.Ms (M+1=253,255,257)；1HNMR(300MHz,CDCl3)8.82(s,1H),1.88(s,3H),1.81(s,3H)。
Embodiment 5
N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] } synthesis of-4-toluene sulfonyl hydrazide:
By bromo-for compound 4-chloro-5-6-(2-(2-fluoro-2-methyl) ethyl-pyrimidin (1677g, 6.62mol, 1eq) join in 50L reactor with chloroform (20L), start mechanical agitation, it is subsequently adding unifor (2474g, 13.23mol, 2eq), it is warming up to backflow after adding, reacts 3 days.TLC (PE:EA=10:1) display raw material reaction is complete.Naturally being down to room temperature, filter, filter cake MTBE washes twice, dries, obtains product 2252g, yield: 84.3%.
Embodiment 6
The synthesis of the bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine:
40L water is joined in 50L reactor, mechanical agitation, add sodium carbonate (4.5kg, 42.45mol, 2.9eq), be warming up to backflow.Be dividedly in some parts compound N '-{ 4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide (5.9kg, 14.63mol, 1eq), finish rear back flow reaction 2h.TLC (PE:EA=2:1) display raw material reaction is complete, is cooled to room temperature.Adding MTBE extraction (10L × 2), merge organic facies, saturated aqueous common salt washed once, and anhydrous sodium sulfate is dried.Concentrate dry, obtain crude product 1.6kg.Decompression distillation, 20pa 50-60 DEG C collects fraction, altogether 1498g.Yield 46.7%.Ms (M+1=219,221)；1H NMR(300MHz,CDCl3)δ9.04(s,1H),8.85(s,1H),1.85(s,3H),1.77(s,3H).
Embodiment 7
The synthesis of 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-formaldehyde:
THF adds in 5L reaction bulb, starts mechanical agitation, adds the bromo-4-of compound 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine (600g, 2.74mol, 1eq), and nitrogen is replaced, and is cooled to-50 DEG C.Dropping isopropylmagnesium chloride (2.3L, 4.657mol, 1.7eq), drips and reacts 2h after finishing.TLC (PE:EA=6:1) shows that raw material reaction is complete ,-50 DEG C of droppings N-formyl-morpholine (945g, 8.219mol, 3eq), drips and finishes rear room temperature reaction overnight.GC monitoring reaction disappears to raw material, drips saturated ammonium chloride cancellation, and MTBE extracts (5L × 2).Merging organic facies, saturated aqueous common salt washed once, and anhydrous sodium sulfate is dried.Concentrating the dry crude product that obtains, cross post, PE:MTBE=15:1 rushes product.Obtain 350g.Yield 76%.Ms (M+1=169.10)；1H NMR(300MHz,CDCl3)δ10.65(s,1H),9.22(s,1H),9.10(s,1H),1.85(s,3H),1.77(s,3H)。
Embodiment 8
The synthesis of 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol:
2L reaction bulb adds 1.5L water, mechanical agitation, is subsequently adding compound 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-formaldehyde (180g, 1.07mol, 1eq), is cooled to 0-5 DEG C.It is dividedly in some parts sodium borohydride (12.2g, 0.32mol, 0.3eq).TLC (PE:EA=2:1) display raw material reaction is complete, and DCM (500ml × 5) extracts, and merges extraction phase anhydrous sodium sulfate and is dried.Concentrate and do to obtain crude product 149g, yield 83%.
Embodiment 9
2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } synthesis of methyl-isoindole quinoline-1,3-diketone:
20L reaction bulb, mechanical agitation, add THF (12L); it is subsequently adding compound 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol (1100g, 6.47mol, 1eq); triphenyl phosphorus (1865g, 7.12mol, 1.1eq); phthalimide (1046g, 7.12mol, 1.1eq); it is cooled to 5 DEG C again, under nitrogen protection, drips DEAD (1238g, 7.12mol; 1.1eq), complete rear room temperature reaction is dripped overnight.TLC (PE:EA=2:1) display raw material reaction is complete, concentrates THF, surplus about 5L volume, 5L water is added in residue, MTBE extracts (5L × 2), and the organic facies 1N sodium hydroxide solution of merging washed once, and aqueous phase extracts (2L × 2) with EA again.Merge all of organic facies anhydrous sodium sulfate to be dried.Concentrating dry, mix silica gel and cross post, PE:EA=4:1 rushes post, obtains product MTBE making beating, dries to obtain sterling 723g.Yield: 37%.
Embodiment 10
The synthesis of [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride:
50L reactor, add ethanol (15L), mechanical agitation, add compound 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine methyl-isoindole quinoline-1,3-diketone (1173g, 3.923mol, 1eq), hydrazine hydrate (490g, 9.8mol, 2.5eq), being warming up to backflow, reaction is overnight.TLC (DCM:MeOH=10:1) display raw material reaction is complete, it is cooled to room temperature, dissolve with MTBE after reactant liquor is spin-dried for, filtering, filter cake MTBE washes twice, and product is washed to aqueous phase by the organic facies of merging 2M HCl (2L), aqueous phase washes twice with DCM again, then adjusting pH=11, DCM to extract (2L × 5) aqueous phase with 15% sodium hydroxide solution, combining extraction liquid anhydrous sodium sulfate is dried.Being concentrated into solvent residue 5L, be transferred in 10L reaction bulb, be cooled to less than 10 DEG C, logical HCl is to becoming salt complete.Filter, filter cake washing with acetone three times, dry and to obtain off-white color solid 835g, yield: 91% altogether.Ms (M+1=170.10)；1H NMR(300MHz,dmso)δ9.16(s,1H),8.99(s,1H),6.88(br,3H),1.77(s,3H),1.70(s,3H)。
Additive method step can also be there is before and after described combination step in addition, it is to be understood that the one or more method steps mentioned in the present invention do not repel or additive method step can also be inserted, except as otherwise noted between these steps specifically mentioned；Will also be understood that, combination annexation between the one or more equipment/devices mentioned in the present invention is not repelled and can also be there are other equipment/devices before and after described unit equipment/device or can also insert other equipment/devices, except as otherwise noted between these two equipment/devices specifically mentioned.And, except as otherwise noted, the numbering of various method steps is only the convenient tool differentiating various method steps, rather than for limiting the ordering of various method steps or limiting the enforceable scope of the present invention, being altered or modified of its relativeness, in the case of without essence change technology contents, when being also considered as the enforceable category of the present invention.
The principle of above-described embodiment only illustrative present invention and effect thereof, not for limiting the present invention.Above-described embodiment all can be modified under the spirit and the scope of the present invention or change by any person skilled in the art.Therefore, art has all equivalence modification or changes that usually intellectual is completed under without departing from disclosed spirit and technological thought such as, must be contained by the claim of the present invention.
Claims (10)
1. a preparation method for structural formula compound as shown in formula L, described compound is [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-
Methylamine hydrochloride, formula L is:
Described method comprises the steps:
1) 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde is added to the water, is dividedly in some parts sodium borohydride reaction and obtains 4-[2-(2-
Fluoro-2-methyl) ethyl]-5-pyrimidine-methanol；
2) 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-methanol, triphenylphosphine and phthalimide are at solvent and noble gas
Under the conditions of with diethyl azodiformate react acquisition 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine methyl-isoindole
Quinoline-1,3-diketone；
3) 2-{4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine } methyl-isoindole quinoline-1,3-diketone and hydrazine hydrate are in a solvent and backflow
Under the conditions of reaction obtain [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-5-methylamine hydrochloride.
2. as claimed in claim 1 method, it is characterised in that: step 1) described in sodium borohydride be dividedly in some parts.
3. as claimed in claim 1 method, it is characterised in that: above-mentioned steps 2) in reaction temperature be-10～10 DEG C.
4. method as claimed in claim 1, it is characterised in that: the preparation side of described 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde
Method comprises the steps:
1) (2-(2-fluoro-2-methyl) ethyl-pyrimidin and unifor back flow reaction in chloroform obtains the bromo-6-of the chloro-5-of 4-
N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] }-4-toluene sulfonyl hydrazide；
2) N'-{4-[the bromo-6-of 5-(2-(2-fluoro-2-methyl) ethyl) pyrimidine] } the back flow reaction acquisition in alkaline aqueous solution of-4-toluene sulfonyl hydrazide
The bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine；
3) the bromo-4-of 5-[2-(2-fluoro-2-methyl) ethyl] pyrimidine first reacts with isopropylmagnesium chloride, then reacts with N-formyl-morpholine and obtain
Obtain 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidinecarboxaldehyde.
5. method as claimed in claim 4, it is characterised in that: (2-(2-fluoro-2-methyl) ethyl-pyrimidin is for using for the bromo-6-of the chloro-5-of 4-
(2-(2-fluoro-2-methyl) ethyl-4-pyrimidone obtains the bromo-6-of 5-with phosphorus oxychloride reaction.
6. method as claimed in claim 5, it is characterised in that: (2-(2-fluoro-2-methyl) ethyl-4-pyrimidone is the bromo-6-of described 5-
The method comprised the steps is used to obtain:
1) 2-fluorine isobutyrate reacts generation 4-fluoro-4-methyl-3-oxo-pentanoic acid first in a solvent with ethyl acetate and potassium tert-butoxide
Ester；
2) 4-fluoro-4-methyl-3-oxo-pentanoate and formamidine acetate react generation [4-(1-fluorine in a solvent and in the basic conditions
-1-methyl-ethyl)-pyrimidine]-2-ketone；
3) [4-(1-fluoro-1-methyl-ethyl)-pyrimidine]-2-ketone generates the bromo-6-of 5-(2-(the fluoro-2-of 2-with bromine generation bromination reaction in a solvent
Methyl) ethyl-4-pyrimidone.
7. method as claimed in claim 6, it is characterised in that: step 1) in, solvent is oxolane.
8. as claimed in claim 6 method, it is characterised in that: step 2) in solvent be methanol, using Feldalat NM regulation pH is alkali
Property.
9. a midbody compound, it is characterised in that described midbody compound be 4-[2-(2-fluoro-2-methyl) ethyl]-5-pyrimidine-
Methanol, the formula J of described compound is:
10. a purposes for midbody compound as claimed in claim 9, for as synthesis [4-(1-fluoro-1-methyl-ethyl)-phonetic
Pyridine] pharmaceutical intermediate of-5-methylamine hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610349669.0A CN106008362B (en) | 2016-05-24 | 2016-05-24 | A kind of preparation method of pyrimidine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610349669.0A CN106008362B (en) | 2016-05-24 | 2016-05-24 | A kind of preparation method of pyrimidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106008362A true CN106008362A (en) | 2016-10-12 |
| CN106008362B CN106008362B (en) | 2018-08-10 |
Family
ID=57094014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610349669.0A Active CN106008362B (en) | 2016-05-24 | 2016-05-24 | A kind of preparation method of pyrimidine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106008362B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831603A (en) * | 2017-01-09 | 2017-06-13 | 辽宁大学 | A kind of preparation method containing fluoropyrimidine compound |
| CN108395408A (en) * | 2018-03-23 | 2018-08-14 | 杰达维（上海）医药科技发展有限公司 | A kind of pharmaceutical intermediate and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1358175A (en) * | 1999-05-01 | 2002-07-10 | 史密丝克莱恩比彻姆有限公司 | Pyrimidinone compounds |
| WO2012008527A1 (en) * | 2010-07-16 | 2012-01-19 | 住友化学株式会社 | Pyrimidine compound and pest-control usage therefor |
| CN102498091A (en) * | 2009-09-16 | 2012-06-13 | 安斯泰来制药株式会社 | Glycine compound |
| CN103601675A (en) * | 2013-10-08 | 2014-02-26 | 南京复兴生物科技有限公司 | Novel preparation method of 5-aminomethyl nicotinic acid |
| WO2015153304A1 (en) * | 2014-04-01 | 2015-10-08 | Merck Sharp & Dohme Corp. | Prodrugs of hiv reverse transcriptase inhibitors |
| WO2016044662A1 (en) * | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
-
2016
- 2016-05-24 CN CN201610349669.0A patent/CN106008362B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1358175A (en) * | 1999-05-01 | 2002-07-10 | 史密丝克莱恩比彻姆有限公司 | Pyrimidinone compounds |
| CN102498091A (en) * | 2009-09-16 | 2012-06-13 | 安斯泰来制药株式会社 | Glycine compound |
| WO2012008527A1 (en) * | 2010-07-16 | 2012-01-19 | 住友化学株式会社 | Pyrimidine compound and pest-control usage therefor |
| CN103601675A (en) * | 2013-10-08 | 2014-02-26 | 南京复兴生物科技有限公司 | Novel preparation method of 5-aminomethyl nicotinic acid |
| WO2015153304A1 (en) * | 2014-04-01 | 2015-10-08 | Merck Sharp & Dohme Corp. | Prodrugs of hiv reverse transcriptase inhibitors |
| WO2016044662A1 (en) * | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| ACS: "RN：1427195-20-7", 《STN REGISTRY数据库》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831603A (en) * | 2017-01-09 | 2017-06-13 | 辽宁大学 | A kind of preparation method containing fluoropyrimidine compound |
| CN106831603B (en) * | 2017-01-09 | 2019-07-02 | 辽宁大学 | A kind of preparation method of fluorine-containing pyrimidine compound |
| CN108395408A (en) * | 2018-03-23 | 2018-08-14 | 杰达维（上海）医药科技发展有限公司 | A kind of pharmaceutical intermediate and preparation method thereof |
| CN108395408B (en) * | 2018-03-23 | 2021-03-09 | 杰达维（上海）医药科技发展有限公司 | Drug intermediate and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106008362B (en) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102002040A (en) | Synthesis method of triazol pyridine ring compound | |
| CN103980253B (en) | Synthetic method for 5-chloro-6-(2-iminopyrrolidinyl-1-yl)methyl-2,4-(1H,3H)pyrimidinedione hydrochloride | |
| CN102491974A (en) | Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride | |
| CN107365275A (en) | The Sai Lexipa of high-purity | |
| CN106008362A (en) | Preparation method of novel pyrimidine derivative | |
| CN105566215A (en) | Preparation method of Stivarga | |
| CN105646373B (en) | A kind of preparation method of 4- amino -2,6- dimethoxypyridins | |
| CN110981816B (en) | Synthesis method of 4-amino-2, 6-dimethoxypyrimidine | |
| CN108707141A (en) | The preparation method of avanaphil | |
| CN105669642A (en) | Revaprzan hydrochloride preparation method | |
| CN103787984B (en) | The preparation method of ticagrelor intermediate 4,6-bis-chloro-5-nitro-2-(rosickyite base) pyrimidine | |
| CN102558042B (en) | 4-bromine-6-methylnicotinicacid and preparation method thereof | |
| CN103333117B (en) | The preparation method of a kind of 4 [(the chloro-2-pyrimidyl of 4-) is amino] cyanophenyl | |
| CN104557877B (en) | A kind of avanaphil intermediate and its preparation method and application | |
| CN104341345B (en) | A kind of synthetic method of 2-methoxyl group-6-ketone-5,6,7,8-tetrahydroquinoline | |
| CN103086962A (en) | Synthetic method for 5-chlorine-2,4-dyhydroxyl pyridine | |
| CN101190927B (en) | Preparation method of 9- [2- (phosphonomethoxy) ethyl ] adenine monoterpentanoyloxymethyl ester | |
| CN103588712A (en) | Pyrimidine compound and preparation method and application thereof | |
| CN110903238A (en) | A kind of preparation method of valdurostat | |
| CN102070524A (en) | Method for preparing 3-cyano-4-halogenated quinoline derivatives | |
| CN105968108B (en) | A kind of method for synthesizing Pabuk former times profit cloth intermediate | |
| CN108395408A (en) | A kind of pharmaceutical intermediate and preparation method thereof | |
| CN106083734A (en) | A kind of method preparing 2 chloropyrimide 4 formic acid | |
| CN108329236B (en) | A kind of preparation method of enzalutamide intermediate | |
| CN104418769A (en) | Compound and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |